Paul Tudor Jones's NVO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 440,617 shares of Novo Nordisk A/S (NVO) worth $16.19 M, representing 0.03% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in NVO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 234,268 shares. Largest reduction occurred in Q2 2025, reducing 230,073 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +206,349 | Add 88.08% | 440,617 | $36.75 |
| Q4 2025 | +234,268 | New Buy | 234,268 | $50.88 |
| Q2 2025 | -230,073 | Sold Out | 0 | $0.00 |
| Q1 2025 | +108,031 | Add 88.52% | 230,073 | $69.44 |
| Q4 2024 | +107,815 | Add 757.82% | 122,042 | $86.02 |
| Q3 2024 | +14,227 | New Buy | 14,227 | $119.07 |
| Q2 2024 | -51,315 | Sold Out | 0 | $0.00 |
| Q1 2024 | -161,191 | Reduce 75.85% | 51,315 | $128.40 |
| Q4 2023 | +51,499 | Add 31.99% | 212,506 | $103.45 |
| Q3 2023 | +108,099 | Add 204.32% | 161,007 | $90.94 |
| Q2 2023 | +4,516 | Add 9.33% | 52,908 | $80.92 |
| Q1 2023 | +48,392 | New Buy | 48,392 | $0.08 |
| Q3 2022 | -24,012 | Sold Out | 0 | $0.00 |
| Q2 2022 | +24,012 | New Buy | 24,012 | $55.72 |
| Q1 2022 | -8,802 | Sold Out | 0 | $0.00 |
| Q4 2021 | +8,802 | New Buy | 8,802 | $56.01 |
Paul Tudor Jones's Novo Nordisk A/S Investment FAQs
Paul Tudor Jones first purchased Novo Nordisk A/S (NVO) in Q4 2021, acquiring 8,802 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Novo Nordisk A/S (NVO) for 16 quarters since Q4 2021.
Paul Tudor Jones's largest addition to Novo Nordisk A/S (NVO) was in Q4 2025, adding 234,268 shares worth $11.92 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 440,617 shares of Novo Nordisk A/S (NVO), valued at approximately $16.19 M.
As of the Q1 2026 filing, Novo Nordisk A/S (NVO) represents approximately 0.03% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Novo Nordisk A/S (NVO) was 440,617 shares, as reported at the end of Q1 2026.